Menu ×


CAR T-Cell Therapy Market Segmentation By Indication (Acute Lymphoblastic Leukemia [ALL], Chronic Lymphocytic Leukemia [CLL], Multiple Myeloma [MM], Diffuse Large B Cell Lymphoma [DLBCL] and Others); By Target Antigen (CD19, CD20, CD22, CD30, GD2 and Others) – Global Demand Analysis & Opportunity Outlook 2028

  • Text Size:

Extensive insights into the Growth of CAR T-Cell Therapy Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More


  • On October 18, 2017, the U.S. Food and Drug Administration (FDA) approved Yescarta (axicabtagene ciloleucel), which is a cell based gene therapy developed for the treatment of certain types of large B-cell lymphoma in adult patients. Yescarta, developed by Kite Pharma, Inc., is the second chimeric antigen receptor (CAR) T cell therapy approved by the U.S. FDA and first approved therapy for the treatment of certain forms of non-Hodgkin lymphoma (NHL).

Introduction to CAR T-Cell Therapy

The immune system of the body is primarily made up of lymphocytes which consist of three kinds of cells: B lymphocytes or B cells, T lymphocytes or T cells and natural killer cells. Chimeric Antigen Receptor T-cell therapy, commonly known as the CAR T-cell therapy, is a form of immunotherapy being developed for use in the treatment of cancer at a genetic as well as cellular level. In recent years, the number of cases of cancer has risen significantly, which is resulting in the need for effective and targeted therapies for its treatment.

The CAR T-cell therapy involves extraction of the patient’s white blood cells, mainly T-cells, which are then modified to contain the gene for chimeric antigen receptor. These cells are then delivered back to the patient’s blood. The chimeric antigen receptor is a protein that specifically binds to the cancerous cells and therefore treats the condition.

Market Size and Forecast

The CAR T-cell therapy market is anticipated to record a CAGR of around 35% over the forecast period, i.e., 2020-2028. The market is segmented by indication, by target antigen and by region. On the basis of indication, the market is further segmented into acute lymphoblastic leukemia (ALL), chronic lymphoblastic leukemia (CLL), multiple myeloma (MM), diffuse large B cell lymphoma (DLBCL) and others, out of which, the DLBCL segment is anticipated to hold the largest share in the CAR T-cell therapy market on account of growing cases of the condition which raise the demand for CAR T-cell therapy. The segment for multiple myeloma is another segment anticipated to observe significant growth in the market as a result of rising research and development in that area. Based on target antigen, the CAR T-cell therapy market is segmented into CD19, CD20, CD22, CD30, GD2 and others. Out of these, the segments for CD19 and CD20 target antigens are anticipated to hold the largest shares in the market. This can be attributed to the high approval rate of therapies containing these antigens. CLICK TO DOWNLOAD SAMPLE REPORT

CAR T Cell Therapy Market Graph

Growth Drivers

Rising Cases of Cancer Globally to Drive the Market Growth

According to the Leukemia & Lymphoma Society, approximately one person in the United States is diagnosed with a form of blood cancer every 3 minutes. Moreover, it was estimated that a total of 176,200 people in the U.S. would be diagnosed with leukemia, myeloma or lymphoma in 2019. Further, leukemia, myeloma and lymphoma were predicted to account for 10% of the total new cancer cases in 2019. The growing cases of various types of cancer all across the globe are estimated to become the major factor responsible for the growth of CAR T cell therapy market. As a result of this, the demand for effective treatment methods for cancer, which are targeted, increases significantly.

Growing Demand for CAR T Cell Therapy as Opposed to Alternate Therapies to Boost the Market Growth

In 2017, the U.S. FDA approved Kymriah, a CAR T cell therapy for the treatment of large B cell lymphoma in adult patients. The therapy, developed by Novartis, can further be used for the treatment of adult patients with acute lymphoblastic leukemia, diffuse large B cell lymphoma (DLBCL) and DLBCL arising due to follicular lymphoma. The property of CAR T cell therapies to be used for various types of cancer and treat multiple forms of lymphoma is a major growth factor for the CAR T cell therapy market.


Side Effects Associated with CAR T-Cell Therapy to Hamper the Market Growth

The various side effects associated with the CAR T cell therapy, such as cytokine release syndrome (CRS), pyrexia, reduced appetite, hypotension, headache, encephalopathy, nausea, bleeding and edema among several others are estimated to restrict the market growth. In addition to the harmful side effects, the high cost of obtaining this therapy is predicted to be another important factor hampering the market growth over the forecast period.

Market Segmentation

Our in-depth analysis of the CAR T-cell therapy market includes the following segments:

By Indication

  • Acute Lymphoblastic Leukemia [ALL]
  • Chronic Lymphocytic Leukemia [CLL]
  • Multiple Myeloma [MM]
  • Diffuse Large B Cell Lymphoma [DLBCL] 
  • Others

By Target Antigen

  • CD19
  • CD20
  • CD22
  • CD30
  • GD2
  • Others

By Region

On the basis of regional analysis, the CAR T-cell therapy market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.

The market for CAR T cell therapy is predicted to hold the leading share in the North America region. This can be mainly attributed to the large share held by the market in the United States. The growing research and developments taking place in the field of CAR T cell therapy and cancer treatments in the region along with increasing number of treatments receiving approval by the U.S. Food and Drug Administration (FDA) are estimated to further boost the market growth. For instance, Kymriah is a CAR T cell therapy manufactured by Novartis and approved by the FDA in 2017. The therapy is for the treatment of acute lymphoblastic leukemia. The market in Europe is anticipated to hold the second largest share in the market as a result of growing approvals of CAR T cell therapies such as Kymriah and Yescarta by the European Medicines Agencies (EMA), which is further predicted to increase the market size over the coming years.

The CAR T-cell therapy market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC,  Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis.
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Top Featured Companies Dominating the Market


Related Reports

Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved